Advanced Ovarian Cancer Pipeline Insight

DelveInsight’s, “Advanced Ovarian Cancer - Pipeline Insight, 2023,” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Advanced Ovarian Cancer Understanding

Advanced Ovarian Cancer: Overview

Advanced Ovarian Cancer means that the cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have Advanced Ovarian Cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of the cancer. Chemotherapy, surgery and targeted cancer drugs are all treatments for Advanced Ovarian Cancer. Some women may have radiotherapy. Targeted cancer drugs can help the body to control the growth of cancer cells. Occasionally doctors suggest radiotherapy for Advanced Ovarian Cancer. Radiotherapy can shrink tumours and reduce symptoms.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Ovarian Cancer.

Advanced Ovarian Cancer Emerging Drugs Chapters

This segment of the Advanced Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Advanced Ovarian Cancer Emerging Drugs

 

Oregovomab: OncoQuest

Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.  In a randomized Phase 2 clinical trial of 97 patients, treatment with Oregovomab in combination with chemotherapy had demonstrated a highly statistically significant and clinically meaningful outcome for both progression-free and overall survival compared to standard of care chemotherapy (carboplatin and paclitaxel). The risk of progression and of death was reduced by more than 50% when compared to control arm, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of advanced ovarian cancer.

 

SC 10914: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

SC10914 is a highly selective inhibitor of PARP enzymes, including PARP1 and PARP2. SC10914 has a similar structure with olaparib. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Ovarian Cancer.

 

Stenoparib: Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Ovarian Cancer.

Further product details are provided in the report……..

Advanced ovarian cancer: Therapeutic Assessment

This segment of the report provides insights about the different advanced ovarian cancer drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Advanced ovarian cancer

There are approx. 60+ key companies which are developing the therapies for advanced ovarian cancer. The companies which have their advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.

 

Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides 
  • Polymer 
  • Small molecule
  • Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Ovarian Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Ovarian Cancer therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Ovarian Cancer drugs.

Advanced Ovarian Cancer Report Insights

  • Advanced Ovarian Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Advanced Ovarian Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Advanced Ovarian Cancer drugs?
  • How many Advanced Ovarian Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Ovarian Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Ovarian Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Ovarian Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Advanced ovarian cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Advanced ovarian cancer – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Advanced ovarian cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Advanced ovarian cancer Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Oregovomab: OncoQuest

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

EP0057: Ellipses Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

DS-6000a: Daiichi Sankyo Company

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Advanced ovarian cancer Key Companies

Advanced ovarian cancer Key Products

Advanced ovarian cancer- Unmet Needs

Advanced ovarian cancer- Market Drivers and Barriers

Advanced ovarian cancer- Future Perspectives and Conclusion

Advanced ovarian cancer Analyst Views

Advanced ovarian cancer Key Companies

Appendix

List of Table

Table 1: Total Products for Advanced Ovarian Cancer

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Advanced Ovarian Cancer

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• OncoQuest
• Allarity Therapeutics
• AstraZeneca
• Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Ellipses Pharma
• Merck KGaA
• Pfizer
• Jiangsu HengRui Medicine Co., Ltd.
• Boehringer Ingelheim
• Impact Therapeutics, Inc.
• Glycotope
• Puma Biotechnology, Inc.
• Bayer
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Daiichi Sankyo, Inc.
• Astellas Pharma Inc

 

Forward to Friend

Need A Quote